Eisai Past Earnings Performance

Past criteria checks 1/6

Eisai's earnings have been declining at an average annual rate of -23%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 2.7% per year. Eisai's return on equity is 5.1%, and it has net margins of 5.4%.

Key information

-23.0%

Earnings growth rate

-23.0%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate2.7%
Return on equity5.1%
Net Margin5.4%
Next Earnings Update07 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Eisai makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ESAI.Y Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24753,22140,970382,177168,009
30 Jun 24733,84532,648387,882169,347
31 Mar 24741,75142,406364,084169,021
31 Dec 23749,46045,421346,208176,070
30 Sep 23759,32948,096346,619174,257
30 Jun 23757,07548,874341,916175,647
31 Mar 23744,40255,432348,139172,999
31 Dec 22737,09826,705373,875169,848
30 Sep 22752,50032,233382,752173,324
30 Jun 22741,59432,690374,428168,422
31 Mar 22756,22647,954356,847171,738
31 Dec 21712,93557,311317,150165,418
30 Sep 21691,25062,508293,153162,699
30 Jun 21679,25359,855282,369161,584
31 Mar 21645,94242,119272,568150,299
31 Dec 20707,88893,682271,476145,248
30 Sep 20713,400120,571261,973139,628
30 Jun 20707,203124,523253,516141,217
31 Mar 20695,621121,767248,554140,116
31 Dec 19661,64696,659244,091146,367
30 Sep 19631,97457,725239,503147,863
30 Jun 19643,53172,747233,180140,143
31 Mar 19642,83463,386223,798144,844
31 Dec 18627,36763,714212,469139,100
30 Sep 18625,10665,679195,229138,461
30 Jun 18611,49954,347186,198140,514
31 Mar 18600,05451,845179,915139,579
31 Dec 17569,81429,048178,312134,955
30 Sep 17554,27630,269178,090123,639
30 Jun 17544,02729,425176,249119,503
31 Mar 17539,09739,358175,633112,478
31 Dec 16530,69655,031175,240110,471
30 Sep 16542,31371,812178,825114,420
30 Jun 16545,60269,227182,036115,750
31 Mar 16547,92254,933188,227122,307
31 Dec 15566,43544,886192,375125,396
30 Sep 15554,91243,871191,627132,652
30 Jun 15554,88543,021192,617135,534
31 Mar 15548,46543,254189,910131,907
31 Dec 14560,79540,15290,324228,412
30 Sep 14561,93815,717126,410192,643
30 Jun 14578,94529,225163,903159,644
31 Mar 14600,36332,955210,544130,544
31 Dec 13590,15243,756223,092120,377

Quality Earnings: ESAI.Y has high quality earnings.

Growing Profit Margin: ESAI.Y's current net profit margins (5.4%) are lower than last year (6.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ESAI.Y's earnings have declined by 23% per year over the past 5 years.

Accelerating Growth: ESAI.Y's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ESAI.Y had negative earnings growth (-14.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (54.6%).


Return on Equity

High ROE: ESAI.Y's Return on Equity (5.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:01
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eisai Co., Ltd. is covered by 27 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Aaron HoCFRA Equity Research